| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Cellectar Biosciences (NASDAQ:CLRB) is set to give its latest quarterly earnings report on Thursday, 2025-11-13. Here's what investors need to know before the announcement.
Analysts estimate that Cellectar Biosciences will report an earnings per share (EPS) of $-2.28.
The announcement from Cellectar Biosciences is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
During the last quarter, the company reported an EPS beat by $0.27, leading to a 1.81% drop in the share price on the subsequent day.
Here's a look at Cellectar Biosciences's past performance and the resulting price change:
| Quarter | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|
| EPS Estimate | -3.66 | -4.8 | -10.5 | -11.1 | -30.0 |
| EPS Actual | -3.39 | -4.2 | -0.3 | -12.0 | -5.4 |
| Price Change % | -2.00 | 0.0 | 5.0 | -9.0 | 0.0 |
Shares of Cellectar Biosciences were trading at $3.56 as of November 11. Over the last 52-week period, shares are down 94.05%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
To track all earnings releases for Cellectar Biosciences visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CLRB
